Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NovoCure Ltd Director's Dealing 2021

Jun 11, 2021

31949_dirs_2021-06-11_e34a19a3-7c31-4eea-a609-2dab44bb1941.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2021-06-09

Reporting Person: Hung David (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-06-09 Restricted Stock Units A 814 Acquired 6714 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-06-09 Options to Buy Ordinary Shares $211.89 A 1499 Acquired 2031-06-09 Ordinary Shares (1499.0) Direct

Footnotes

F1: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2022 annual general meeting of shareholders.

F2: Options to buy 1,499 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2022 annual general meeting of shareholders.